Phibro Animal Health delivered $1.296 billion in fiscal 2025 net sales (+27% YoY), with adjusted EBITDA of $183.7 million (+65%) and adjusted EPS of $2.09 (+76%). Growth was driven by the October 2024 acquisition of the Zoetis medicated feed additive portfolio (~$208 million incremental annual revenues). Fiscal 2026 guidance: $1.43-1.48 billion net sales (+12%) and $230-240 million Adjusted EBITDA.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Strategic priorities include integration of the Zoetis MFA portfolio, growth in poultry vaccines in Latin America, and expansion of nutritional specialty products. Three segments: Animal Health, Mineral Nutrition, Performance Products. Strengths include the dramatically expanded MFA position post-acquisition, vertical integration in mineral nutrition, and exposure to ethanol-fermentation processing aids. Risks include Zoetis deal integration execution, antimicrobial stewardship pressure on MFAs, and concentration in production-animal segments.
Topics Covered
• Corporate Overview and History
• Strategic Directions and 2026-2030 Priorities
• Financial Performance and Segment Breakdown
• SWOT Analysis
• Business Segment Analysis
• Technology and Innovation Pipeline
• M&A, Partnerships and Licensing Activity
• Competitive Positioning Against Top 10 Peers
• Strategic Conclusions and Outlook
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Business Segment Analysis
7. Technology and Innovation
8. M&A and Partnerships
9. Competitive Positioning
10. Strategic Conclusions
11. Appendix
List of Tables
Table 1. Phibro Animal Health — Consolidated Revenue and Operating Income 2021-2025
Table 2. Phibro Animal Health — Revenue by Segment 2023-2025
Table 3. Phibro Animal Health — Revenue by Geography 2023-2025
Table 4. Phibro Animal Health — Top Products by Revenue 2025
Table 5. Phibro Animal Health — R&D Investment and Pipeline 2023-2025
Table 6. Phibro Animal Health — M&A and Licensing Activity 2023-2026
Table 7. Phibro Animal Health — SWOT Analysis Summary
Table 8. Phibro Animal Health — Competitive Positioning vs. Top 10 Peers
Table 9. Phibro Animal Health — Capital Allocation 2023-2025
Table 10. Phibro Animal Health — 2026 Guidance and Strategic Milestones
